THE BROAD INSTITUTE, INC.;BAYER AKTIENGESELLSCHAFT;BAYER PHARMA AKTIENGESELLSCHAFT;DANA-FARBER CANCER INSTITUTE, INC.;THE BOARD INSTITUTE INC.
发明人:
LEWIS, TIMOTHY A.,WU, XIAOYUN,GREULICH, HEIDI,MEYERSON, MATTHEW,ELLERMANN, MANUEL,LIENAU, PHILIP,EIS, KNUT,WENGNER, ANTJE MARGRET,KOPITZ, CHARLOTTE CHRISTINE,LANGE, MARTIN
申请号:
CA3052220
公开号:
CA3052220A1
申请日:
2018.02.01
申请国别(地区):
CA
年份:
2018
代理人:
摘要:
The present invention features improved compounds, especially the compound having the structure (1). Compositions and methods of identifying patients having cancer using biomarkers (e.g., PDE3A, PDE3B, SLFN12 and/or CREB3L1) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention.